In line with this, TDP2 has been shown to be overexpressed in lung cancer [6, 7] and knockdown of TDP2 remarkably increases lung cancer cells’ sensitivity to Top2 inhibitors, underscoring the importance of targeting TDP2 enzyme in clinic treatment. The gene discussed is TOP2A; the disease is lung carcinoma.